FLGT Stock Overview
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for FLGT from our risk checks.
Fulgent Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.75 |
| 52 Week High | US$44.09 |
| 52 Week Low | US$20.51 |
| Beta | 1.42 |
| 1 Month Change | -4.51% |
| 3 Month Change | -20.56% |
| 1 Year Change | -30.81% |
| 3 Year Change | -76.33% |
| 5 Year Change | 188.19% |
| Change since IPO | 126.03% |
Recent News & Updates
Recent updates
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Mar 01
Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Feb 21Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
Jan 17Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 09Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Apr 19Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27Wait For Fulgent Genetics To Grow Up
Oct 13We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Jul 26Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04Fulgent Is Putting Its Cash Bonanza To Work
May 15These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics: Now The Going Could Get Much Tougher
Apr 10Fulgent Genetics: COVID Bolstered The Underlying Business
Mar 17Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business
Feb 27Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy
Feb 09Fulgent Genetics: Sell Volatility
Jan 26Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet
Jan 25Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy
Jan 09Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot
Dec 20I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease
Dec 14Fulgent: Now Cheap Enough
Dec 06Shareholder Returns
| FLGT | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -1.9% | 2.4% | -3.7% |
| 1Y | -30.8% | 0.8% | 20.5% |
Return vs Industry: FLGT underperformed the US Healthcare industry which returned 0.8% over the past year.
Return vs Market: FLGT underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| FLGT volatility | |
|---|---|
| FLGT Average Weekly Movement | 5.3% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FLGT's share price has been volatile over the past 3 months.
Volatility Over Time: FLGT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,184 | Ming Hsieh | www.fulgentgenetics.com |
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
Fulgent Genetics, Inc. Fundamentals Summary
| FLGT fundamental statistics | |
|---|---|
| Market cap | US$619.54m |
| Earnings (TTM) | -US$167.82m |
| Revenue (TTM) | US$289.21m |
2.1x
P/S Ratio-3.7x
P/E RatioIs FLGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLGT income statement (TTM) | |
|---|---|
| Revenue | US$289.21m |
| Cost of Revenue | US$184.76m |
| Gross Profit | US$104.46m |
| Other Expenses | US$272.28m |
| Earnings | -US$167.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
| Earnings per share (EPS) | -5.61 |
| Gross Margin | 36.12% |
| Net Profit Margin | -58.03% |
| Debt/Equity Ratio | 0.1% |
How did FLGT perform over the long term?
See historical performance and comparison